Systemic availability of the active metabolite hydroxy-fasudil after administration of fasudil to different sites of the human gastrointestinal tract

Journal of Clinical Pharmacology

Volumn 47, Issue 1, 2007, Pages 19-25

  Hinderling, Peter H ^a   Karara, Adel H ^b   Tao, Ben ^c   Pawula, Maria ^d   Wilding, Ian ^e   Lu, Ming ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Clinical Pharmacology Department   (United States)

^c DAIICHI SANKYO INC   (United States)

^d HUNTINGDON LIFE SCIENCES   (United Kingdom)

^e PHARMACEUTICAL PROFILES LTD   (United Kingdom)

Author keywords

Antianginal drug; Fasudil; Gastrointestinal tract; Hydroxyl fasudil; Remote controlled capsule; Rho kinase; Site of drug absorption

Indexed keywords

FASUDIL;

ADULT; AGED; ARTICLE; ASCENDING COLON; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL TRACT; HEADACHE; HUMAN; HUMAN EXPERIMENT; ILEUM; LIVER FUNCTION TEST; MALE; NORMAL HUMAN; NOSE CONGESTION; OPEN STUDY; POWDER; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOLUTION AND SOLUBILITY; STABLE ANGINA PECTORIS; SYNCOPE; TABLET; VOLUNTEER;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ADULT; BIOLOGICAL AVAILABILITY; CAPSULES; CROSS-OVER STUDIES; GASTROINTESTINAL TRACT; HUMANS; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; TELEMETRY;

EID: 33845804228     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006293767     Document Type: Article

References (18)

1. Asano T, Suzuki T, Tsuchiya M, et al. Vasodilator actions of HA1077 in vitro and in vivo putatively mediated by the inhibition of protein kinase. Br J Pharmacol. 1989 ; 98: 1091-1100.
2. Set M, Takuwa Y, Sasaki Y. The molecular mechanism of vasospasm and the attenuation by fasudil. Nippon Yakurigaku Zasshi. 1999 ; 114 (suppl 1). 66P - 70P.
3. Negoro N, Hoshiga M, Seto M, et al. The kinase inhibitor fasudil (HA-1077) reduces initial hyperplasia through inhibiting migration and enhancing cell loss of vascular smooth muscle cells. Biochem Biophys Res Commun. 1999 ; 262: 211-215.
4. Batchelor TJP, Sadaba RJ, Ishola A, et al. Rho-kinase inhibitors prevent agonist-induced vasospasm in human internal mammary artery. Br J Pharmacol. 2001 ; 132: 302-308.
5. Rouge N, Buri P, Doelker E. Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. Int J Pharm. 1996 ; 136: 117-139.
6. Knutson L, Odlind B, Hullgren R. A new technique for segmental jejunal perfusion in man. Am J Gastroenterol. 1989 ; 84: 1278-1284.
7. Wilding IR. The Enterion™ capsule: a novel technology for understanding the biopharmaceutical complexity of new molecular entities (NMEs). Drug Delivery Technology. 2001 ; 1: 50-52.
8. Schuster O, Hugemann B. Course of development of the HF capsule-variations and method related findings. In: Rietbrock N, Woodcock BG, Staib AH, Loew D, eds. Drug Absorption at Different Regions of the Human Gastro-intestinal Tract: Methods of Investigation and Results. Wiesbaden, Germany: Vieweg Braunschweig ; 1987: 28-38. Methods in Clinical Pharmacology ; vol 7.
9. Wilding IR, Hirst PH, Connor AL. Development of a new engineering-based capsule for human drug absorption studies. Pharm Sci Technol Today. 2000 ; 3: 385-392.
10. Oo C, Snell P, Barrett J, et al. Pharmacokinetics and delivery of the anti-influenza prodrug oseltamivir to the small intestine and colon using site-specific delivery capsules. Int J Pharm. 2003 ; 257: 297-299.
11. Martin NE, Read KA, Martin LL, et al. Pharmacoscintigraphic assessment of the regional drug absorption of the dual ACE/NEP inhibitor, M100240, in healthy volunteers. J Clin Pharmacol. 2003 ; 43: 529-538.
12. DeSesso JM, Jacobsen CF. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food Chem Toxicol. 2001 ; 39: 209-209.
13. Paine MF, Khaligi M, Fisher JM, et al. Characterization of interintestinal and intraintestinal variations in human CYP 3A-dependent metabolism. J Pharmacol Exp Ther. 1997 ; 283: 1552-1562.
14. Mouly S, Paine MF. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res. 2003 ; 20: 1595-1599.
15. Lindell M, Karlsson MO, Lennernaes H, et al. Variable expression of CYP and P-gp genes in the human small intestine. Eur J Clin Invest. 2003 ; 33: 493-499.
16. Suzuki H, Sugiyama Y. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur J Pharm Sci. 2000 ; 12: 3-12.
17. Kunta JR, Sinko PJ. Intestinal drug transporters: in vivo function and clinical importance. Curr Drug Metab. 2004 ; 5: 109-124.
18. Ford D, Howard A, Hirst BH. Expression of the peptide transporter hPepT1 in human colon: a potential route for colonic protein nitrogen and drug absorption. Histochem Cell Biol. 2003 ; 119: 37-43.